Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
PGEN Transcript
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Unknown3-19
The earnings call reflects mixed signals: strong cash position and anticipated demand for PRGN-2012 suggest positive sentiment. However, increased net loss, operational risks, and competitive pressures temper optimism. The Q&A highlights management's cautious communication about FDA interactions and market capture, which adds uncertainty. Considering these factors, the stock price is expected to remain stable.
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Unknown3-19
The earnings call presents a mixed sentiment. While there are positive elements like strong cash position and potential revenue from PRGN-2012, there are concerns over increased net loss and supply chain risks. The Q&A highlights FDA interactions and market strategy, but management's evasiveness on key timelines adds uncertainty. Overall, the financial health and strategic outlook balance out the negatives, leading to a neutral sentiment prediction.
PGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
